drugset / Trial / NCT02418949

Summary

This study evaluates a new rehabilitation approach for stroke survivors in the chronic phase of recovery in which the combination of drug therapy (cyproheptadine) and active movement practice (AMP) is used to encourage increased voluntary muscle control and strength.

Timeline

Start
2015-11
Primary completion
2019-08
Completion
2022-03-23

Outcome

Met primary endpoint

paper The Cyproheptadine group displayed significant reduction in grip termination time, in comparison with the Placebo group (p<0.05). PMID 36054974 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyproheptadine Small molecule 8 mg Oral